periodic reminder of mRNA vs. protein levels in CD4+ T cells Ming "Tommy" Tang

We're a month out from Commencement & Ph.D. Hooding Ceremonies!🤯 Check out some of the *amazing* projects supported by Duke Graduate School Fellowships this academic year: bit.ly/3JeZutY Trinity College at Duke Duke Environment Duke Department of Population Health Sciences Duke Department of Cell Biology Duke Engineering

Really interesting paper in Nature Immunology today (Broquet et al.) They found that people who recover from sepsis have a reduced cancer risk in the years that follow (vs. matched people with non-septic infections): This was recapitulated in a controlled setting in mice - mice

Evolocumab as an immunomodulator in glioma: A window of opportunity trial evaluating PCSK9 inhibition to enhance surface MHC-I on tumor medrxiv.org/content/10.110… Kirit Singh

Glioma Surgeons: Think the tumor cells in your 5-ALA-treated patients are fluorescing? Think again! Section on Tumors NYU Langone Health Perlmutter Cancer Center at NYU Langone Health nature.com/articles/s4155…

🧠✨ We’re thrilled to welcome these 3 great minds: Grace Futch, MD (Grace Futch) & Aden Mendoza, MD, of Duke University School of Medicine; & Molly Monsour, MD (Molly Monsour) of @USouthFlorda. We can’t wait to see them scrub in, step up, and shape the future of neurosurgery. #Match2025

In glioma, T cell immunotherapies are limited by the quantity of available T cells. Kirit Singh Peter Fecci Mustafa Khasraw (find me in BlueSky) & team address this challenge in preclinical models by peripheral injection of autologous T cells after pre-treatment with IL-7. Full report